Tarsus Pharmaceuticals, Inc. TARS Business Segments — Sales & Marketing
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Tarsus Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:SellingAndMarketingExpense.
The official record: Tarsus Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Tarsus Pharmaceuticals, Inc.'s business segments — sales & marketing.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Tarsus Pharmaceuticals, Inc.'s business segments — sales & marketing?
- Tarsus Pharmaceuticals, Inc. (TARS) reported business segments — sales & marketing of $84.48M in Q1 2026.
- How has Tarsus Pharmaceuticals, Inc.'s business segments — sales & marketing changed year-over-year?
- Tarsus Pharmaceuticals, Inc.'s business segments — sales & marketing increased by 40.1% year-over-year, from $60.29M to $84.48M.
- What is the long-term trend for Tarsus Pharmaceuticals, Inc.'s business segments — sales & marketing?
- Over 3 years (2022 to 2025), Tarsus Pharmaceuticals, Inc.'s business segments — sales & marketing has grown at a 134.0% compound annual growth rate (CAGR), from $20.89M to $267.68M.
- What does business segments — sales & marketing mean?
- Reflects the costs associated with promoting, advertising, and distributing the company's commercial products to healthcare providers and patients. This is a critical indicator of the company's commercial scaling efforts and market penetration strategy.